55results about How to "Accurate prognosis" patented technology

A method of optimising a model Mx suitable for use in data analysis and determining a prognostic outcome specific to a particular subject (input vector x), the subject comprising a number of variable features in relation to a scenario of interest for which there is a global dataset D of samples also having the same features relating to the scenario, and for which the outcome is known is disclosed. In one implementation, the method includes: (a) determining what number and a subset Vx of variable features will be used in assessing the outcome for the input vector x; (b) determining what number Kx of samples from within the global data set D will form a neighbourhood about x; (c) selecting suitable Kx samples from the global data set which have the variable features that most closely accord to the variable features of the particular subject x to form the neighbourhood Dx; (d) ranking the Vx variable features within the neighbourhood Dx in order of importance to the outcome of vector x and obtaining a weight vector Wx for all variable features Vx; (e) creating a prognostic model Mx, having a set of model parameters Px and the other parameters from (a)-(d); (f) testing the accuracy of the model Mx at e) for each sample from Dx; (g) storing both the accuracy from (f), and the model parameters developed in (a) to (e); (h) repeating (a) and/or (b) whilst applying an optimisation procedure to optimise Vx and/or Kx, to determine their optimal values, before repeating (c)-(h) until maximum accuracy at (f) is achieved.

An agricultural harvesting machine includes different working units, an input and display unit, a memory and evaluation unit, and a control device for influencing adjustable operating parameters of the working units, at least one set criterium being stored in the memory and evaluation unit, and, based on at least one crop material parameter and/or operating parameter that was determined in the harvesting process, and based on the at least one set criterium, a prognosis regarding the attainability of an actual harvesting goal is formulated, the prognosis being taken into account in the adjustment of the operating parameters.

A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.

By means of a proteomic approach, the markers of hepatocellular carcinoma (HCC) in the liver of a knockout mouse (MAT1A−/−) have been identified for the MAT1A gene (deficient in the synthesis of S-adenosylmethionine). 27 proteins have been detected the expression thereof is altered in, at least, 50% of the analysed tumours. Amongst them, 13 proteins have been validated in biopsies of patients with HCC of different etiology, and 7 of them have been validated in biopsies of patients with liver cirrhosis, a stage prior to the development of HCC, which makes it possible to differentiate between prior stages of the disease and even between different etiologies (viral and alcoholic). Having a panel of markers available may contribute to more accurately defining the alterations associated with the development of HCC and thus facilitate prognosis and diagnosis of this disease.

Disclosed are systems, media, and methods for providing a genomic search engine application comprising: a plurality of indices, recorded in the computer storage, the indices comprising tokenized genomic data; a software module providing an indexing pipeline, the indexing pipeline ingesting genomic data and annotation associated with the genomic data, tokenizing the data while preserving gene names and gene variant names, and updating the indices with the tokenized data; and a software module presenting a user interface allowing a user to enter a user query; a software module providing a query engine, the query engine accepting the user query, selecting one or more relevant indices, and applying a ranking formula to the selected indices to return ranked results.

At least one embodiment relates to an image analysis system for tumor classification. The system is configured for receiving at least one digital image of a tissue sample; analyzing the at least one received image for identifying immune cells and tumor cells in the at least one received image; for each of the identified tumor cells, determining the distance of the tumor cell to the nearest immune cell; computing a proximity measure as a function of the determined distances; in dependence on the proximity measure, classifying the identified tumor cells into tumor cells of an inflammatory tumor or as tumor cells of a non-inflammatory tumor; and storing the classification result on a storage medium and/or displaying the classification result on a display device.

The present invention relates to a method for early prediction of a prostate cancer patient's response to hormonal treatment. In one embodiment, the method of the present invention involves assaying a body fluid, such as plasma or serum, from a prostate cancer patient for the presence of elevated levels of chromogranin A (CgA). Elevated levels of CgA may indicate neuroendocrine differentiation of cells within the prostate tumor, and may require altering the patient's treatment. In a further embodiment of the method of the present invention, periodic assays for CgA are conducted for a patient undergoing hormonal treatment for prostate cancer. The results of these assays are correlated to determine if the patient's levels of CgA are high (greater than 100 ng/mL) or increasing. Such assays may also be carried out in conjunction with assays for total prostate specific antigen (tPSA).

A method for predicting whether a patient suffering from a prostate cancer is at risk of experiencing a cancer progression or recurrence which comprises the steps of : obtaining a Gleason score of said prostate tumor sample; assessing the proportion of NF-kB localized in the nuclei of said tumor sample with regard to all NF-kB present in said tumor sample.

The invention belongs to the technical field of detection kits, and particularly relates to a kit for aided-diagnosis and prognostic evaluation on glioblastoma based on a gene CLCF1 and a use method thereof. The kit comprises a PCR (polymerase chain reaction) primer pair for amplifying the gene CLCF1 and a PCR primer pair for amplifying a housekeeping gene GAPDH. The kit has the advantages that the obvious difference of the gene CLCF1 in transcription expression levels of LGG (brain lower grade glioma) and GBM (glioblastoma multiforme) is found for the first time, the prognostic condition of apatient with the glioblastoma is well judged by the expression level of the gene CLCF1, and the gene CLCF1 can be used as the index for independently judging the prognostic condition of the glioblastoma after determining by Cox multi-factor regression analysis; after the expression condition of the transcription level of the gene CLCF1 is detected, the severity of the glioblastoma can be diagnosed, and the prognostic condition of the patient can be predicted.

The present invention concerns particular biomarkers for diagnosing and/or prognosticating colorectal cancer, in particular in a non-invasive manner. The methods and compositions concern analysis of methylation patterns of one or more genes from a set of 29 genes identified as described herein. In certain embodiments, the gene set includes at least P15.INK4b, SST, GAS7, CNRIP1, and PIK3CG.

The invention belongs to the technical field of biology, and particularly relates to a gene mutation site group of NK/T cell lymphoma and a kit and application thereof. The invention provides a gene mutation site group of NK/T cell lymphoma, which can be used for evaluating molecular typing of NK/T cell lymphoma, predicting prognosis of a patient and guiding medication of the patient. According tothe kit, an IlluminaMiseq sequencing platform and performance sequencing are adopted, a series of mutant genes related to NK/TCL diseases can be efficiently and accurately detected, the detection period is short, the detection cost is low, the application range is wide, and the accuracy is high.

Disclosed is a method for predicting cancer prognosis, comprising: forming gene pairs by using a plurality of genes to be tested; determining clusters for the formed gene pairs through a clustering method; calculating a distribution of each gene pair based on the determined cluster; and selecting reference gene pairs for determining a class based on the calculated distribution.

The invention discloses an internal reference substance for detecting bladder cancer serum miRNA. The internal reference substance is single hsa-miR-193a-5p or a mixture of hsa-miR-193a-5p and hsa-miR-16-5p. The invention also discloses detection primers of the internal reference substance. The detection primers comprises primers for detecting hsa-miR-193a-5p (shown in the formulas of SEQ ID NO: 1-3) or/and hsa-miR-16-5p (shown in the formulas of SEQ ID NO: 4-6). The internal reference substance and the detection primers can be used for preparation of a kit for detecting a bladder cancer serum internal reference substance and for detection on the bladder cancer serum miRNA internal reference.

A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.